Triple receptor agonist targeting GIP, GLP-1, and Glucagon receptors simultaneously. An emerging research compound with a growing body of published literature examining its metabolic mechanisms.
Retatrutide (also referenced in the literature as LY3437943) is a novel triple agonist peptide that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Its triple-receptor mechanism distinguishes it from the single and dual agonists that preceded it in the research literature.
What I noticed when first reviewing the Retatrutide literature was how quickly the research base developed. Phase-level clinical trials have been published examining this compound's behaviour, which gives researchers a significantly richer data set to reference compared to many synthetic peptides of similar novelty.
My experience with the research protocols around GLP/GIP agonists suggests that Retatrutide's triple-receptor profile makes it a compound of particular interest for metabolic research programs. Researchers working in this space frequently cite the mechanistic differences between Retatrutide and semaglutide or tirzepatide as a key reason for including it in comparative study designs.
Our Retatrutide is synthesised to 98%+ purity and verified by mass spectrometry and HPLC at an independent ISO/IEC 17025-accredited laboratory. Batch #2606 CoA is published on the Lab Results page.